2023
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participants
2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1
2021
The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study.
Raj D, Sohn M, Charytan D, Himmelfarb J, Ikizler T, Mehrotra R, Ramezani A, Regunathan-Shenk R, Hsu J, Landis J, Li H, Kimmel P, Kliger A, Dember L. The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360 2021, 2: 445-455. PMID: 35369018, PMCID: PMC8786005, DOI: 10.34067/kid.0006132020.Peer-Reviewed Original ResearchConceptsGut microbiomeStool samplesMicrobiome compositionMetabolomic profilesCLINICAL TRIAL REGISTRY NAMEWeighted UniFrac distancesStudy of patientsTRIAL REGISTRY NAMEUniFrac distancesMicrobiome diversityPretreatment to post-treatmentMaintenance hemodialysisUremic toxicityClinical trialsIntestinal microbiomeMicrobiomePost-treatmentREGISTRY NAMEGutPatientsHemodialysisMetabolome compositionFrequent sample collectionRegistration numberESKD
2010
In-Center Hemodialysis Six Times per Week versus Three Times per Week
Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, Gorodetskaya I, Greene T, James S, Larive B, Lindsay R, Mehta R, Miller B, Ornt D, Rajagopalan S, Rastogi A, Rocco M, Schiller B, Sergeyeva O, Schulman G, Ting G, Unruh M, Star R, Kliger A. In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal Of Medicine 2010, 363: 2287-2300. PMID: 21091062, PMCID: PMC3042140, DOI: 10.1056/nejmoa1001593.Peer-Reviewed Original ResearchConceptsLeft ventricular massPhysical health composite scoresFrequent hemodialysisComposite outcomeVascular accessVentricular massSelf-reported depressionConventional hemodialysisCardiac magnetic resonance imagingConventional hemodialysis groupErythropoiesis-stimulating agentsRate of hospitalizationSerum albumin concentrationComposite scoreSelf-reported physical healthCognitive performanceMagnetic resonance imagingMaintenance hemodialysisSecondary outcomesBlood pressureLaboratory markersCenter hemodialysisClinical trialsMineral metabolismHealth Survey